We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$8.54B
$55.6M 10.49%
1,603,932
+818,277
+104% +$24M
CYTK icon
2
Cytokinetics
CYTK
$10.6B
$46.3M 8.73%
853,862
+534,352
+167% +$32.3M
ROIV icon
3
Roivant Sciences
ROIV
$23.6B
$43.9M 8.28%
4,150,009
+1,358,139
+49% +$14.9M
BOXX icon
4
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$37.9M 7.15%
351,482
+33,362
+10% +$3.57M
BBIO icon
5
BridgeBio Pharma
BBIO
$16.4B
$32M 6.05%
1,264,570
+714,766
+130% +$19.5M
RPRX icon
6
Royalty Pharma
RPRX
$26.2B
$31.2M 5.88%
1,181,332
+460,031
+64% +$12.8M
KROS icon
7
Keros Therapeutics
KROS
$197M
$25.1M 4.74%
548,916
+210,673
+62% +$11.3M
INSM icon
8
PUT
Insmed
INSM
$22.3B
$13.5M 2.54%
200,800
+199,100
+11,712% +$7.72M
IMVT icon
9
Immunovant
IMVT
$7.93B
$12.6M 2.38%
476,543
+415,780
+684% +$11.8M
ABUS icon
10
Arbutus Biopharma
ABUS
$845M
$10.2M 1.92%
3,289,260
+1,215,077
+59% +$3.65M
INSM icon
11
CALL
Insmed
INSM
$22.3B
$10.1M 1.9%
+150,000
New +$5.82M
MRK icon
12
Merck
MRK
$322B
$9.38M 1.77%
75,750
+75,450
+25,150% +$9.72M
RZLT icon
13
Rezolute
RZLT
$453M
$8.88M 1.68%
+2,063,962
New +$7.09M
SLDB icon
14
Solid Biosciences
SLDB
$791M
$8.05M 1.52%
1,420,422
+1,217,218
+599% +$10.9M
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.28B
$7.86M 1.48%
436,608
+255,697
+141% +$4.46M
PCSC
16
DELISTED
Perceptive Capital Solutions
PCSC
$7.54M 1.42%
+750,000
New +$7.55M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.5B
$6.99M 1.32%
51,263
+2,679
+6% +$365K
TECX
18
Tectonic Therapeutic
TECX
$536M
$5.88M 1.11%
356,878
+27,307
+8% +$437K
QURE icon
19
uniQure
QURE
$2.75B
$5.48M 1.03%
1,222,676
+929,826
+318% +$4.53M
ABSI icon
20
Absci
ABSI
$1.17B
$5.23M 0.99%
1,698,529
+1,111,545
+189% +$5.15M
VKTX icon
21
Viking Therapeutics
VKTX
$3.89B
$4.84M 0.91%
91,227
+76,826
+533% +$5.04M
ALKS icon
22
Alkermes
ALKS
$8.11B
$4.74M 0.89%
196,577
+39,977
+26% +$981K
SPY icon
23
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$772B
$4.35M 0.82%
8,000
-44,000
-85% -$23M
BBOT
24
BridgeBio Oncology
BBOT
$659M
$4.13M 0.78%
404,138
+638
+0.2% +$6.57K
ANAB icon
25
AnaptysBio
ANAB
$1.55B
$3.9M 0.74%
155,799
+154,799
+15,480% +$3.6M
1
2 3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.